12-24-2025, 10:02 AM
I'm a cardiology fellow, and I'm managing an increasing number of elderly patients with newly diagnosed atrial fibrillation who have multiple comorbidities like renal impairment and a high fall risk, making the standard anticoagulation decision incredibly complex. I understand the CHA2DS2-VASc and HAS-BLED scores, but applying them in real-world, frail patients where the risks of stroke and bleeding both seem high leaves me uncertain about the best path forward. For experienced clinicians, how do you navigate atrial fibrillation management in this challenging population? What factors beyond the scores most influence your choice between a DOAC and warfarin, or even deciding against anticoagulation, and how do you effectively communicate this nuanced risk-benefit analysis to patients and their families?